Valter Croci
Nerviano Medical Sciences(IT)
Publications by Year
Research Areas
Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Cancer therapeutics and mechanisms, Quinazolinone synthesis and applications, DNA Repair Mechanisms
Most-Cited Works
- → Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents(2004)489 cited
- → PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer(2007)240 cited
- → A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity(2008)213 cited
- → PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity(2006)161 cited
- → Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor(2009)126 cited
- → Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.(2009)103 cited
- → Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors(2010)81 cited
- → First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery(2008)66 cited
- → Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding(2010)62 cited
- → Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing(2010)62 cited